Ondine Biomedical Inc. (LON:OBI - Get Free Report) reached a new 52-week high on Monday . The stock traded as high as C$15.00 and last traded at C$14.40, with a volume of 1843874 shares changing hands. The stock had previously closed at C$14.40.
Ondine Biomedical Price Performance
The company has a current ratio of 1.36, a quick ratio of 8.26 and a debt-to-equity ratio of 25.95. The firm has a market cap of C$104.26 million, a P/E ratio of -4.37 and a beta of 0.10. The business has a 50-day moving average of C$9.41 and a two-hundred day moving average of C$9.88.
About Ondine Biomedical
(
Get Free Report)
Ondine Biomedical is a life sciences company leading the charge in breakthrough photodisinfection-based therapies to prevent and treat serious infections, including those caused by existing, emerging, and antimicrobial-resistant pathogens.
Our vision is a world free from infections. We have created a patented, platform technology (photodisinfection) to provide simple solutions to complex infections across different therapeutic areas in healthcare and industry settings.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Ondine Biomedical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ondine Biomedical wasn't on the list.
While Ondine Biomedical currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
